Recommended Pages at gsk.com
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
gsk.com — “GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas” View full resource at gsk.com
Most Recently Shared on March 20, 2012 at 5:12 pm By:
eyeonfda Pharma and Health Lawyer
GSK announces positive vote from #FDA panel for pazopanib in certain advanced soft tissue sarcomas - http://t.co/xojTkIE4
GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
gsk.com — “GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands” View full resource at gsk.com
Most Recently Shared on March 15, 2012 at 11:59 am By:
Glaxo finds a European buyer for that consumer-brand portfolio: Omega Pharma, in a 470m euro/$613m deal. PR: http://t.co/kpNxQjb5 $GSK
GlaxoSmithKline European regulatory update on Pandemrix™
gsk.com — “GlaxoSmithKline European regulatory update on Pandemrix™” View full resource at gsk.com
Most Recently Shared on July 21, 2011 at 9:09 pm By:
GlaxoSmithKline European regulatory update on Pandemrixâ„¢: GlaxoSmithKline (GSK) announced today that the Europ... http://bit.ly/pZzs2y
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD
gsk.com — “GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD” View full resource at gsk.com
Most Recently Shared on June 2, 2011 at 7:39 pm By:
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD. http://bit.ly/lng3Oy
GlaxoSmithKline announces non-core OTC products to be divested
gsk.com — “GlaxoSmithKline announces non-core OTC products to be divested” View full resource at gsk.com
Most Recently Shared on April 14, 2011 at 2:47 pm By:
eyeonfda Pharma and Health Lawyer
GSK announces non-core OTC products to be divested http://ow.ly/4AcIS
GSK publishes 2010 Corporate Responsibility Report
gsk.com — “GSK publishes 2010 Corporate Responsibility Report” View full resource at gsk.com
Most Recently Shared on March 30, 2011 at 11:03 am By:
eyeonfda Pharma and Health Lawyer
GSK publishes 2010 Corporate Responsibility Report - http://ow.ly/4pnHu
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
gsk.com — “GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction” View full resource at gsk.com
Most Recently Shared on March 23, 2011 at 3:18 pm By:
eyeonfda Pharma and Health Lawyer
GSK says it will no longer pursue global approval for use of Avodartâ„¢ to reduce the risk of prostate cancer - http://ow.ly/4kM4i
GSK supports recovery efforts to help those affected by the Japan earthquake
gsk.com — “GSK supports recovery efforts to help those affected by the Japan earthquake” View full resource at gsk.com
Most Recently Shared on March 18, 2011 at 1:31 pm By:
Worldwide support for Japan. Kudos to @GSK: RT @GSK: GSK helps those affected by the Japan earthquake. http://gsk.to/e14ink #CHT_Health
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint
gsk.com — “GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint” View full resource at gsk.com
Most Recently Shared on March 11, 2011 at 2:53 pm By:
eyeonfda Pharma and Health Lawyer
GSK, Tolerx say phase III DEFEND-1 study of otelixizumab in type 1 #diabetes didn't meet primary endpoint - http://ow.ly/4cu04
Regulatory update: Nimenrix® (MenACWY vaccine)
gsk.com — “GlaxoSmithKline (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its candidate conjugate meningitis vaccine, Nimenrix®,” View full resource at gsk.com
Most Recently Shared on March 2, 2011 at 2:49 pm By:
eyeonfda Pharma and Health Lawyer
GSK submits Marketing Authorisation Application (MAA) to EMA for candidate conjugate meningitis vaccine, Nimenrix® - http://ow.ly/46mkF
GSK revises US Avandia label to include new restrictions on use
gsk.com — “GlaxoSmithKline (GSK) today announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines.” View full resource at gsk.com
Most Recently Shared on February 8, 2011 at 12:53 am By:
GSK revises US Avandia label to include new restrictions on use: GlaxoSmithKline (GSK) today announced revised U... http://bit.ly/ihJcNE
GSK revises US Avandia label to include new restrictions on use
gsk.com — “GlaxoSmithKline (GSK) today announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines.” View full resource at gsk.com
Most Recently Shared on February 7, 2011 at 8:04 pm By:
Gannett Healthcare Health News
Breaking news: GSK revises US Avandia label to include new restrictions on use http://tinyurl.com/4gbods8
GSK and Actelion discontinue clinical development of almorexant
gsk.com — “GSK and Actelion discontinue clinical development of almorexant” View full resource at gsk.com
Most Recently Shared on January 28, 2011 at 3:21 pm By:
eyeonfda Pharma and Health Lawyer
GSK and Actelion discontinue clinical development of almorexant http://ow.ly/3LZas
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
gsk.com — “GlaxoSmithKline (GSK) announced today the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation.” View full resource at gsk.com
Most Recently Shared on January 25, 2011 at 8:19 pm By:
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma: GlaxoSmithKline (GSK) ... http://bit.ly/e7kQea
GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition
gsk.com — “GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition” View full resource at gsk.com
Most Recently Shared on December 13, 2010 at 2:23 pm By:
eyeonfda Pharma and Health Lawyer
Interesting move - GSK boosts Nutritional Healthcare business with acquisition of Maxinutrition http://ow.ly/3offA
